CCRM is a Canadian, public-private partnership funded by the Government of Canada, the Province of Ontario, and leading academic and industry partners. It supports the development and manufacturing of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy (CGT). CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, dedicated funding and unique infrastructure. In 2022, CCRM established OmniaBio Inc., a pre-clinical to commercial-stage CDMO for manufacturing gene-modified cells and viral vectors for CGTs. CCRM launched in June 2011. Visit www.ccrm.ca.